ReviewIranian journal of neurology2014
Cardiovascular effects of fingolimod: A review article.
Review in Iranian journal of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Novel Finding of Retinal Aneurysmal Alterations in Patients Undergoing Fingolimod Therapy for Multiple Sclerosis.Neurology and therapy · 2026Article
- Unmasking the Silent Threat: Prevalence of Cardiovascular Risk Factors in MS Patients in Bucharest, Romania.Journal of clinical medicine · 2025Article
- A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer.Pharmaceutics · 2023Article
- Updates and advances in multiple sclerosis neurotherapeutics.Neurodegenerative disease management · 2023Review
- The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review.Inflammopharmacology · 2022Review
- Sphingosine 1 phosphate promotes hypertension specific memory T cell trafficking in response to repeated hypertensive challenges.Frontiers in physiology · 2022Article
- ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1PMolecules (Basel, Switzerland) · 2021Article
- A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.Cardiovascular drugs and therapy · 2021Review
- Fingolimod (FTY720) Preserves High Energy Phosphates and Improves Cardiac Function in Heterotopic Heart Transplantation Model.International journal of molecular sciences · 2020Article
- Morpholino Analogues of Fingolimod as Novel and Selective S1PInternational journal of molecular sciences · 2020Article
- Review
- Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.International journal of physiology, pathophysiology and pharmacology · 2019Review
- Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) Attenuates Myocardial Fibrosis in Post-heterotopic Heart Transplantation.Frontiers in pharmacology · 2017Article
- Elevated Nuclear and Cytoplasmic FTY720-Phosphate in Mouse Embryonic Fibroblasts Suggests the Potential for Multiple Mechanisms in FTY720-Induced Neural Tube Defects.Toxicological sciences : an official journal of the Society of Toxicology · 2016Article
- Sphingosine-1-phosphate metabolism: A structural perspective.Critical reviews in biochemistry and molecular biology · 2015Review
- The preventive effect ofAvicenna journal of phytomedicineArticle
- Livedo Reticularis in Association with Fingolimod: A Case Report.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic auto-immune disease. Most therapeutic strategies for treatment of this disease direct immune modulation and control of inflammatory processes. First-line therapeutic agents showed moderate efficacy and frequent side-effects with moderate efficacy in trials. Their parental administration and limited long-term adherence restrict their efficacy compared with second-line therapies. Fingolimod as a second-line therapeutic agent has been shown to reduce annualized relapse rate, risk of disability progression and inflammatory activity of relapsing MS. Safety and efficacy FTY720: Safety and efficacy issues are the main metrics for judgment of drug efficacy. In this article, we focus on cardiovascular effects of FTY720 treatment. Effect of FTY720 on rate and rhythm, impact of FTY720 on endothelial cells, its atheroprotective effects, its effects on cardiac transplantation outcomes, vascular complications of FTY720, effects of FTY720 on endocrine functions and interaction of FTY720 with cardioactive agents are explained in this review article.
Indexed as
Identifiers
25422729PMC4240927W2155786753What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.